RankingsPricing
  1. US-listed companies
  2. CATALYST PHARMACEUTICALS, INC.
  3. Financials
  4. Research & development

CATALYST PHARMACEUTICALS, INC.CPRX

Market cap
$2.8B
P/E ratio
SummaryFinancials
Period EndResearch & development (Million USD)YoY (%)
Dec 31, 202413-86.42%
Dec 31, 202393+370.72%
Dec 31, 202220+16.85%
Dec 31, 202117+2.66%
Dec 31, 202016-12.45%
Dec 31, 201919-5.40%
Dec 31, 201820+75.11%
Dec 31, 201711+0.05%
Dec 31, 201611-3.66%
Dec 31, 201512+16.64%
Dec 31, 201410-72.20%
Dec 31, 201336+28.61%
Dec 31, 201228+10.37%
Dec 31, 201126

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating income Operating expenses Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSAdjusted EPSDividend payout ratio (%)Dividend per shareAdjusted DPSEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)